Literature DB >> 3496734

Alpha 1-antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases.

S Eriksson.   

Abstract

alpha 1-Antitrypsin (AAT) deficiency in adults predisposes to lung and liver disease, but its natural history is incompletely known. To better characterize the liver disease, all known deceased adult Swedish patients known to us with homozygous (PiZZ) AAT-deficiency, who had undergone autopsy during the 20-year period 1963-82 were reviewed. Of 94 such patients, 35 had cirrhosis (27 males and eight females) with a mean age at death of 65.5 +/- 10.5 (SD) years compared to 53.6 +/- 12.8 years (p less than 0.01) for the 59 non-cirrhotic patients. The longer survival suggests less severe lung disease in the cirrhotic group. Clinically these patients most frequently presented with ascites or other signs of portal hypertension. Evidence of alcohol overconsumption, chronic viral hepatitis, or autoimmune disease was rare. Aside from low plasma AAT levels, laboratory and other clinical features were indistinguishable from those of decompensated cirrhosis of any etiology. The prognosis was generally grave with a mean survival of two years after diagnosis. Fourteen of the 35 cirrhotics (10 males and four females) had primary liver cancer (PLC) at autopsy. We conclude that cirrhosis and PLC are more frequent complications in elderly patients with AAT-deficiency than was previously known. These complications had a marked male predominance.

Entities:  

Mesh:

Year:  1987        PMID: 3496734

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  19 in total

Review 1.  Update on Alpha-1 Antitrypsin Deficiency in Liver Disease.

Authors:  Praveena Narayanan; Pramod K Mistry
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-06-30

2.  Genetic studies on a new deficiency gene (PI*Ztun) at the PI locus.

Authors:  D B Whitehouse; C M Abbott; J U Lovegrove; I McIntosh; C J McMahon; G Mieli-Vergani; A P Mowat; D A Hopkinson
Journal:  J Med Genet       Date:  1989-12       Impact factor: 6.318

3.  Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice.

Authors:  J A Carlson; B B Rogers; R N Sifers; M J Finegold; S M Clift; F J DeMayo; D W Bullock; S L Woo
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

4.  Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.

Authors:  Shuling Guo; Sheri L Booten; Mariam Aghajan; Gene Hung; Chenguang Zhao; Keith Blomenkamp; Danielle Gattis; Andrew Watt; Susan M Freier; Jeffery H Teckman; Michael L McCaleb; Brett P Monia
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

Review 5.  Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency.

Authors:  David R Nelson; Jeffrey Teckman; Adrian M Di Bisceglie; David A Brenner
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-23       Impact factor: 11.382

6.  Non-invasive assessment for alpha-1 antitrypsin deficiency-associated liver disease: new insights on steatosis and fibrosis in Pi*ZZ carriers.

Authors:  Siyer Roohani; Frank Tacke
Journal:  Transl Gastroenterol Hepatol       Date:  2019-12-12

Review 7.  Liver disease.

Authors:  S D Ryder; R Williams
Journal:  Postgrad Med J       Date:  1994-03       Impact factor: 2.401

8.  Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study.

Authors:  Karin F Kok; René H te Morsche; Martijn G H van Oijen; Joost P H Drenth
Journal:  BMC Gastroenterol       Date:  2010-02-20       Impact factor: 3.067

Review 9.  alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.

Authors:  R A Sandhaus
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

10.  Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency.

Authors:  Virginia C Clark; Renumathy Dhanasekaran; Mark Brantly; Farshid Rouhani; Pamela Schreck; David R Nelson
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-24       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.